Evidence map›Paper›PMID 22732108›Full record

Trial reportDiabetes & vascular disease research2013

Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research.

Concetta Irace, Simona De Luca, Ermal Shehaj, Claudio Carallo, Antonio Loprete, Faustina Scavelli, Agostino Gnasso

Registry-linked trialOpen access · bronzeAbstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Diabetes & vascular disease research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05478707 (Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes), which is not on this map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05478707 phase2recruitingstarted 2023, after this paper: background citation

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Ran2023Enrolled47Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Type 1, Endothelial DysfunctionArmsDulaglutide, Placebo
PMID 29310645PMID 24742660PMID 27295427PMID 27436611PMID 27633186PMID 33219433PMID 33259257PMID 34075130PMID 34339111PMID 9490243PMID 30291013PMID 11842075other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Review
  14. Review
  15. Endothelial dysfunction in chronic kidney disease: a clinical perspective.American journal of physiology. Heart and circulatory physiology · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Vascular Aging: Assessment and Intervention.Clinical interventions in aging · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Concetta IraceDepartment of Clinical and Experimental Medicine, University Magna Græcia Catanzaro, University Campus Salvatore Venuta, Viale Europa, 88100 Catanzaro, Italy.
Simona De Luca
Ermal Shehaj
Claudio Carallo
Antonio Loprete
Faustina Scavelli
Agostino Gnasso
Magna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The GLP-1 receptor agonist exenatide has been approved for adjunctive treatment of type 2 diabetes. Continuous GLP-1 infusion improves endothelial function in vivo; no evidence about a beneficial effect of exenatide on vascular function has been published. The aim of our observational study was to evaluate whether exenatide would improve brachial artery function evaluated by the flow mediated dilation (FMD) technique, compared with glimepiride, in subjects with type 2 diabetes. FMD time course was assessed by ultrasound, after 5 min forearm ischaemia, at baseline and after 16-week treatment. At the end of the study FMD was significantly higher in subjects who assumed exenatide compared with glimepiride (9.1 ± 3.6 vs. 5.6 ± 1.0, p = 0.01). Even if limited by the small number of studied subjects, who were not matched in the two treatment groups, this research study represents the first FMD evidence suggesting that chronic administration of exenatide improves arterial dilation.

Indexed as

AgedBlood Flow VelocityBrachial ArteryDiabetes Mellitus, Type 2Drug Therapy, CombinationElectrocardiographyEndothelium, VascularExenatideFemaleGlucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsMaleMetforminMiddle AgedPeptidesExenatideglimepirideGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorHypoglycemic AgentsMetforminPeptidesReceptors, GlucagonSulfonylurea CompoundsVenoms

Identifiers

PMID22732108
OpenAlexW2153003051

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.